Clinical Trials Logo

Clinical Trial Summary

Pyrotinib is an oral tyrosine kinase inhibitor targeting both HER-1 and HER-2 receptors.This study is a single-arm, prospective, open label clinical study for evaluating the efficacy and safety of neoadjuvant pyrotinib and trastuzumab plus docetaxel given as neoadjuvant treatment in HER2 positive early stage or locally advanced breast cancer.


Clinical Trial Description

Neoadjuvant therapy is the standard treatment for locally advanced breast cancer and is used to reduce tumors to make them operable, and to increase breast-conserving rates. In recent years, the anti-HER2 treatment mode, which is double-blocked by a combination of dual-targeted drugs, has obtained clinical approval in adjuvant therapy and neoadjuvant therapy. Pyrotinib is an oral tyrosine kinase inhibitor targeting both HER-1 and HER-2 receptors. Based on previous clinical studies, we designed the study to explore the possibility of Pyrotinib in combination with Trastuzumab plus Docetaxel given as neoadjuvant treatment in HER2 positive early stage or locally advanced breast cancer. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03735966
Study type Interventional
Source Henan Cancer Hospital
Contact
Status Completed
Phase Phase 2
Start date November 20, 2018
Completion date October 20, 2020

See also
  Status Clinical Trial Phase
Completed NCT01904903 - Cardiac Safety Study in Patients With HER2 + Breast Cancer Phase 2
Completed NCT02476539 - Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast Cancer Phase 1
Completed NCT01840306 - Exosomal and Free Extracellular RNAs and Proteins as Predictive Biomarkers for HER2 Therapies in Breast Cancer
Recruiting NCT01785420 - Pre Operative Trastuzumab in Operable Breast Cancer Phase 3
Recruiting NCT05132582 - A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer Phase 3
Terminated NCT00817362 - Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer Phase 2
Not yet recruiting NCT03947242 - Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer. N/A
Terminated NCT02213744 - MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients Phase 2/Phase 3
Completed NCT02362958 - A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer Phase 2
Completed NCT02614794 - A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer Phase 2
Completed NCT03013504 - A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients Phase 3
Completed NCT02682693 - Denosumab as an add-on Neoadjuvant Treatment (GeparX) Phase 2
Completed NCT02125344 - A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) Phase 3
Active, not recruiting NCT04539938 - A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer Phase 2
Recruiting NCT05252988 - Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib Phase 2
Terminated NCT02963363 - Adapted Physical Activity for Breast Cancer HER2 Positive Patient N/A
Completed NCT02705859 - Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study) Phase 1
Active, not recruiting NCT02993198 - A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging Phase 2